Details of the Drug

General Information of Drug (ID: DMAH70G)

Drug Name

Molindone

Synonyms

Molindona; Molindonum; Molindone Monohydrochloride; Molindona [INN-Spanish]; Molindone (INN); Molindone (MOL); Molindone [INN:BAN]; Molindonum [INN-Latin]; (+-)-Molindone; 3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one; 3-Ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5H)-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydro-4H-indol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-4,5,6,7-tetrahydro-1H-indol-4-one

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1], [2]

Therapeutic Class

Antipsychotic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

276.37

Topological Polar Surface Area (xlogp)

1.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Elimination: 2% of drug is excreted from urine in the unchanged form [3]
Metabolism: The drug is metabolized via the hepatic [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.63 micromolar/kg/day [5]

Chemical Identifiers

Formula: C16H24N2O2
IUPAC Name: 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one
Canonical SMILES: CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C
InChI: InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3
InChIKey: KLPWJLBORRMFGK-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 23897
ChEBI ID: CHEBI:6965
CAS Number: 7416-34-4
DrugBank ID: DB01618
TTD ID: D09TPF
ACDINA ID: D00444

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Binder	[6], [7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Schizophrenia

ICD Disease Classification

6A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Molindone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Molindone and Iloperidone.	Schizophrenia [6A20]	[18]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Molindone and Thiothixene.	Schizophrenia [6A20]	[18]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Molindone and Asenapine.	Schizophrenia [6A20]	[18]
-----------

Coadministration of a Drug Treating the Disease Different from Molindone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Molindone and Oliceridine.	Acute pain [MG31]	[19]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Molindone and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[20]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Molindone and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[20]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Molindone and Cariprazine.	Bipolar disorder [6A60]	[18]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Molindone when combined with Acetylcholine.	Cataract [9B10]	[21]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Molindone and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[22]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Molindone and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[22]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Molindone and Cyclandelate.	Dementia [6D80-6D8Z]	[23]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Molindone and OPC-34712.	Depression [6A70-6A7Z]	[18]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Molindone and Esketamine.	Depression [6A70-6A7Z]	[24]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Molindone and Mepenzolate.	Digestive system disease [DE2Z]	[18]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Molindone and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[25]
Deutetrabenazine	DMUPFLI	Major	Additive antidopaminergic effects by the combination of Molindone and Deutetrabenazine.	Dystonic disorder [8A02]	[26]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Molindone and Nebivolol.	Hypertension [BA00-BA04]	[23]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Molindone and Levamlodipine.	Hypertension [BA00-BA04]	[23]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Molindone and TAK-491.	Hypertension [BA00-BA04]	[23]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Molindone and Clevidipine butyrate.	Hypertension [BA00-BA04]	[23]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Molindone and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[18]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Molindone and ITI-007.	Insomnia [7A00-7A0Z]	[18]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Molindone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[27]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Molindone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[28]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Molindone and Lasmiditan.	Migraine [8A80]	[29]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Molindone and Flibanserin.	Mood disorder [6A60-6E23]	[30]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Molindone and Phenindamine.	Nasopharyngitis [CA00]	[18]
Lorcaserin	DMG6OYJ	Moderate	Increased risk of hyperprolactinemic effects by the combination of Molindone and Lorcaserin.	Obesity [5B80-5B81]	[31]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Molindone and Lofexidine.	Opioid use disorder [6C43]	[23]
Opicapone	DM1BKA6	Moderate	Additive hypotensive effects by the combination of Molindone and Opicapone.	Parkinsonism [8A00]	[32]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Molindone and Methylscopolamine.	Peptic ulcer [DA61]	[18]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Molindone and Silodosin.	Prostate hyperplasia [GA90]	[23]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Molindone when combined with Neupro.	Restless legs syndrome [7A80]	[32]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Molindone and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[18]
-----------


⏷ Show the Full List of 31 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium sulfate anhydrous	E00303	24497	Desiccant; Diluent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Molindone 25 mg tablet	25 mg	Oral Tablet	Oral
Molindone 10 mg tablet	10 mg	Oral Tablet	Oral
Molindone 5 mg tablet	5 mg	Oral Tablet	Oral
Molindone Hydrochloride 25mg tablet	25mg	Tablet	Oral
Molindone Hydrochloride 10mg tablet	10mg	Tablet	Oral
Molindone Hydrochloride 5mg tablet	5mg	Tablet	Oral
Molindone Hydrochloride 50mg tablet	50mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 207).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 017111.
3	BDDCS applied to over 900 drugs
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002083.
7	Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998 Mar;3(2):123-34.
8	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
9	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
10	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
11	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
12	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
13	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
14	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
15	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
16	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
17	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
18	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
19	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
20	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
21	Multum Information Services, Inc. Expert Review Panel.
22	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
23	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
24	Cerner Multum, Inc. "Australian Product Information.".
25	Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
26	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
27	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
28	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
29	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
30	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
31	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
32	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]